(Q61767257)

2

0 references

B.K. Haller

3

0 references

A. Boberg

4

0 references

U. Edbäck

5

0 references

D. Bernasconi

6

0 references

S. Buttò

7

0 references

H. Gaines

8

0 references

N. Imami

9

0 references

F. Gotch

10

0 references

F. Lori

11

0 references

J. Lisziewicz

12

0 references

E. Sandström

13

0 references

B. Hejdeman

14

0 references

L Gudmundsdotter

1

0 references

B Wahren

2

0 references

B K Haller

3

0 references

A Boberg

4

0 references

U Edbäck

5

0 references

D Bernasconi

6

0 references

S Buttò

7

0 references

H Gaines

8

0 references

N Imami

9

0 references

F Gotch

10

0 references

F Lori

11

0 references

J Lisziewicz

12

0 references

E Sandström

13

0 references

B Hejdeman

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

14

0 references

language of work or name

English

0 references

publication date

July 2011

0 references

26 July 2011

0 references

published in

Vaccine

0 references

volume

29

0 references

issue

33

0 references

page(s)

5558-5566

0 references

5558-66

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Generalized immune activation as a direct result of activated CD4+ T cell killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Innate immune recognition and activation during HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Enhancement of HIV Type 1 Antigen-Specific CD4+ T Cell Memory in Subjects with Chronic HIV Type 1 Infection Receiving an HIV Type 1 Immunogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Control of viral rebound through therapeutic immunization with DermaVir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Safety of hydroxyurea in the treatment of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Effects of Human Leukocyte Antigen Class I Genetic Parameters on Clinical Outcomes and Survival after Initiation of Highly Active Antiretroviral Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Rational development of a stable liquid formulation for nanomedicine products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

DermaVir: a novel topical vaccine for HIV/AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Therapeutic immunization for HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064